Background: This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed. Trial Registration No: NCT03473223 ( Link Sponsor: CSL Behring Trial Status: recruiting Enrolling Centers: Worldwide: 17400 participants Core Study Team Basel:
© Christian Mueller, 2012 - 2022 │ DisclaimerImprintWebmaster │ Last Update: May 2022
Ina-Maria Ferel Ph.D. Natascha Herr Michael Freese, UP Dr. Samyut Shrestha Noemi Glarner Beate Hartmann Ph.D. Michael Kolbe Iris Huber Mario Grossenbacher Alessandra Sanzone Annemarie Acket Fatima Aliyeva Androniki Papachristou Michele Gafner Svetlana Stanojkovic